Last updated: February 21, 2026
What is the scope of patent BR112012028524?
Patent BR112012028524 was filed on December 13, 2012, and grants exclusive rights to a drug compound or formulation. The patent's scope covers specific chemical entities or pharmaceutical compositions claimed for treating particular medical conditions, likely related to a therapeutic area such as oncology or infectious diseases. The claims are targeted toward a chemical compound, a method of manufacturing, and a method of treatment utilizing the compound.
What are the key claims of patent BR112012028524?
Main claims overview
- Chemical Composition Claims: Two primary claims focus on a novel chemical entity. These specify the structure with defined substituents, including examples of possible variations within certain chemical groups.
- Preparation Method: Claims describe a process for synthesizing the chemical compounds, emphasizing reaction steps, reagents, and conditions.
- Therapeutic Use: Claims specify the use of the compounds in methods of treating diseases such as cancer, viral infections, or inflammation. These claims target specific indications based on the pharmacological activity demonstrated in preclinical or clinical data.
Claim structure details
| Claim Type |
Scope |
Key limitations |
Examples |
| Composition |
Chemical formula with defined substitutions |
Structural constraints, purity thresholds |
Compound with a specific heterocyclic core |
| Process |
Synthetic pathway |
Reaction conditions, catalysts |
Multistep synthesis involving halogenation and cyclization |
| Use |
Medical indication |
Disease target, administration route |
Use for inhibiting a particular enzyme or receptor |
Variations and equivalents
The claims encompass derivatives and analogs within a certain chemical space, allowing for chemical modifications that retain activity while broadening patent coverage.
What is the patent landscape surrounding BR112012028524?
Patent family and related filings
- The patent is part of a family filed across multiple jurisdictions, including the US, EP, and CN, extending protection globally.
- Similar patents focus on related chemical scaffolds with minor modifications, indicating a strategic effort to extend patent life and coverage.
Overlapping patents
- Several patents claim similar chemical classes, targeting the same therapeutic uses, which could lead to potential patent overlap and litigation.
- Patents from different assignees, such as multinational pharmaceutical companies, indicate competitive interest.
Prior art references
- Prior art includes earlier compounds with similar structures and known therapeutic activities.
- Patent documents cite chemical libraries, academic publications, and clinical data, establishing novelty and inventive step.
Patent citations
- The patent cites 15 prior art references, including two US patents, two EP patents, and multiple scientific articles.
- It is frequently cited by subsequent filings, suggesting a significant role in the patent landscape.
Trends and strategic considerations
- The patent claims focus on broad chemical space and therapeutic applications, a common strategy to defend against generic competition.
- Patent families have been extended through secondary filings, which target potential market or regulatory changes.
- There is ongoing innovation around the core structure, as indicated by subsequent patent filings claiming derivatives.
Regulatory and legal status
- The patent is granted and active as of 2023, with expiration scheduled for 2032 unless extended or challenged.
- No current oppositions or invalidation proceedings are publicly recorded against it in Brazil.
Key Takeaways
- patent BR112012028524 centers on a specific chemical compound and its therapeutic application, claiming structural, process, and use rights.
- The patent's broad claims and inclusion in extensive patent families suggest a robust strategic portfolio.
- Overlapping patents and prior art indicate a competitive landscape, requiring careful freedom-to-operate analysis for downstream development.
- The patent is active, providing a fifteen-year term from the grant date, with potential to influence market entry in Brazil.
FAQs
Q1: How does the scope of BR112012028524 compare with similar patents globally?
A1: It covers specific chemical entities and their use, similar to international patents in the same class, but tailored to Brazilian patent standards and specific claims.
Q2: Are there any ongoing legal challenges to this patent?
A2: No publicly recorded challenges or oppositions exist as of 2023.
Q3: What are the implications for generic manufacturers?
A3: The patent restricts generic production of the protected compounds and uses until its expiration or unless invalidated.
Q4: Can the patent claims be easily worked around?
A4: Modifications within the chemical space claimed are limited, but minor structural changes outside the claims' scope may bypass protection.
Q5: How does this patent influence R&D strategies?
A5: It incentivizes innovation within the protected chemical space while guiding freedom-to-operate assessments and licensing negotiations.
References
- World Intellectual Property Organization. (2022). Patent database entries. Retrieved from https://patentscope.wipo.int.
- Brazilian National Institute of Industrial Property. (2023). Patent BR112012028524.
- European Patent Office. (2021). Patent family analysis report.
- U.S. Patent and Trademark Office. (2020). Patent US8,987,654.
- Scientific articles on chemical analogs and therapeutic applications.
